WRN Promoter CpG Island Hypermethylation Does Not Predict a Favourable Outcome for Irinotecan-treated Metastatic Colorectal Cancer Patients

被引：0
|
作者：
Bosch, L. J. W. [1 ]
Luo, Y. [2 ]
Lao, V. V. [3 ]
Snaebjornsson, P. [1 ]
Trooskens, G. [4 ]
Vlassenbroeck, I. [5 ]
Mongera, S. [1 ]
Tang, W. [3 ]
Welcsh, P. [3 ]
Herman, J. [6 ]
Koopman, M. [7 ]
Nagtegaal, I. [8 ]
Punt, C. J. A. [9 ]
van Criekinge, W. [4 ]
Meijer, G. A. [1 ]
Monnat, R. J. [3 ]
Carvalho, B. [1 ]
Grady, W. M. [3 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Ghent, B-9000 Ghent, Belgium
[5] MDxHealth SA, Liege, Belgium
[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Univ Med Ctr Utrecht, Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
来源：
JOURNAL OF PATHOLOGY | 2015年 / 237卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
    Bosch, Linda J. W.
    Luo, Yanxin
    Lao, Victoria V.
    Snaebjornsson, Petur
    Trooskens, Geert
    Vlassenbroeck, Ilse
    Mongera, Sandra
    Tang, Weiliang
    Welcsh, Piri
    Herman, James G.
    Koopman, Miriam
    Nagtegaal, Iris D.
    Punt, Cornelis J. A.
    van Criekinge, Wim
    Meijer, Gerrit A.
    Monnat, Raymond J., Jr.
    Carvalho, Beatriz
    Grady, William M.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4612 - 4622
  • [2] Promoter CpG island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in metastatic colorectal cancer
    Bosch, L.
    Trooskens, G.
    Snaebjornsson, P.
    Haan, J.
    Koopman, M.
    Tol, J.
    de Meyer, T.
    Louwagie, J.
    Dehaspe, L.
    van Grieken, N. C. T.
    Ylstra, B.
    Verheul, H.
    van Engeland, M.
    Nagtegaal, I.
    Herman, J. G.
    Punt, C. J. A.
    van Criekinge, W.
    Carvalho, B.
    Meijer, G. A.
    VIRCHOWS ARCHIV, 2014, 465 : S326 - S326
  • [3] MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer
    Wang, Chuntao
    Liu, Yanliang
    Guo, Wenyi
    Zhu, Xu
    Ahuja, Nita
    Fu, Tao
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7337 - 7343
  • [4] Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients
    Labriet, Adrien
    Levesque, Eric
    De Mattia, Elena
    Cecchin, Erika
    Jonker, Derek
    Couture, Felix
    Simonyan, David
    Buonadonna, Angela
    D'Andrea, Mario
    Villeneuve, Lyne
    Toffoli, Giuseppe
    Guillemette, Chantal
    PHARMACOGENOMICS, 2019, 20 (17) : 1179 - 1187
  • [5] hSRBC promoter CpG island hypermethylation as resistant predictive biomarker of oxaliplatin based chemotherapy in metastasic colorectal cancer patients
    Moutinho, Catia
    Martinez-Cardus, Anna
    Santos, Cristina
    Navarro-Perez, Valentin
    Martinez-Balibrea, Eva
    Esteve, Albert Abad
    Salazar, Ramon
    Esteller, Manel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
    Bosch, Linda J. W.
    Trooskens, Geert
    Snaebjornsson, Petur
    Coupe, Veerle M. H.
    Mongera, Sandra
    Haan, Josien C.
    Richman, Susan D.
    Koopman, Miriam
    Tol, Jolien
    de Meyer, Tim
    Louwagie, Joost
    Dehaspe, Luc
    van Grieken, Nicole C. T.
    Ylstra, Bauke
    Verheul, Henk M. W.
    van Engeland, Manon
    Nagtegaal, Iris D.
    Herman, James G.
    Quirke, Philip
    Seymour, Matthew T.
    Punt, Cornelis J. A.
    van Criekinge, Wim
    Carvalho, Beatriz
    Meijer, Gerrit A.
    ONCOTARGET, 2017, 8 (38) : 63140 - 63154
  • [7] WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Kawasaki, Takako
    Ohnishi, Mutsuko
    Suemoto, Yuko
    Kirkner, Gregory J.
    Liu, Zhiqian
    Yamamoto, Hiroyuki
    Loda, Massimo
    Fuchs, Charles S.
    Ogino, Shuji
    MODERN PATHOLOGY, 2008, 21 (02) : 150 - 158
  • [8] Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer
    Amatu, Alessio
    Sartore-Bianchi, Andrea
    Moutinho, Catia
    Belotti, Alessandro
    Bencardino, Katia
    Chirico, Giuseppe
    Cassingena, Andrea
    Rusconi, Francesca
    Esposito, Anna
    Nichelatti, Michele
    Esteller, Manel
    Siena, Salvatore
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2265 - 2272
  • [9] Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer
    de Vogel, Stefan
    Wouters, Kim A. D.
    Gottschalk, Ralph W. H.
    van Schooten, Frederik J.
    de Goeij, Anton F. P. M.
    de Bruine, Adriaan P.
    Goldbohm, Royle A.
    van den Brandt, Piet A.
    Weijenberg, Matty P.
    van Engeland, Manon
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (11) : 3086 - 3096
  • [10] 5′-CpG Island Promoter Hypermethylation of the CAV-1 Gene in Breast Cancer Patients of Kashmir
    Syeed, Nidda
    Hussain, Firdous
    Husain, Syed Akhtar
    Siddiqi, Mushtaq A.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (01) : 371 - 375
12345